Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2012

01-12-2012 | Editorial

S-nitrosylation of Ras in breast cancer

Authors: Harvey E Marshall, Matthew W Foster

Published in: Breast Cancer Research | Issue 6/2012

Login to get access

Abstract

Elevated expression of nitric oxide synthase 2 has been recently shown to correlate with poor survival in estrogen receptor-negative breast cancer. In an article in Breast Cancer Research, Switzer and colleagues identify the transcription factor Ets-1 as a critical mediator of nitric oxide-dependent oncogenic gene expression in basal-like breast cancer. This pathway is driven by S-nitrosylation of wild-type Ras, which leads to mitogen-activated protein kinase-dependent phosphorylation and activation of Ets-1. These results establish a new role for S-nitrosylation in mediating an aggressive breast cancer phenotype.
Literature
1.
Switzer CH, Cheng RY, Ridnour LA, Glynn SA, Ambs S, Wink DA: Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer. Breast Cancer Res. 2012, 14: R125-10.1186/bcr3319.CrossRefPubMedPubMedCentral
2.
Iyer AK, Azad N, Wang L, Rojanasakul Y: Role of S-nitrosylation in apoptosis resistance and carcinogenesis. Nitric Oxide. 2008, 19: 146-151. 10.1016/j.niox.2008.04.019.CrossRefPubMedPubMedCentral
3.
Tang CH, Wei W, Liu L: Regulation of DNA repair by S-nitrosylation. Biochim Biophys Acta. 2012, 1820: 730-735. 10.1016/j.bbagen.2011.04.014.CrossRefPubMed
4.
Sha Y, Marshall HE: S-nitrosylation in the regulation of gene transcription. Biochim Biophys Acta. 2012, 1820: 701-711. 10.1016/j.bbagen.2011.05.008.CrossRefPubMed
5.
Switzer CH, Glynn SA, Cheng RY, Ridnour LA, Green JE, Ambs S, Wink DA: S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol Cancer Res. 2012, 10: 1203-1215. 10.1158/1541-7786.MCR-12-0124.CrossRefPubMedPubMedCentral
6.
Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, Tzeng EE, Geller DA, Billiar TR, Harris CC: p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med. 1998, 4: 1371-1376. 10.1038/3957.CrossRefPubMed
7.
Gochman E, Mahajna J, Shenzer P, Dahan A, Blatt A, Elyakim R, Reznick AZ: The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans. Acta Histochem. 2012, 114: 827-835. 10.1016/j.acthis.2012.02.004.CrossRefPubMed
8.
Wang J, Torbenson M, Wang Q, Ro JY, Becich M: Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastic primary prostate cell cultures and prostatectomy specimen. Urol Oncol. 2003, 21: 117-122. 10.1016/S1078-1439(02)00208-9.CrossRefPubMed
9.
Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Martin DN, Switzer CH, Hudson RS, Wink DA, Lee DH, Stephens RM, Ambs S: Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Investig. 2010, 120: 3843-3854. 10.1172/JCI42059.CrossRefPubMedPubMedCentral
10.
Lander HM, Hajjar DP, Hempstead BL, Mirza UA, Chait BT, Campbell S, Quilliam LA: A molecular redox switch on p21(ras). Structural basis for the nitric oxide-p21(ras) interaction. J Biol Chem. 1997, 272: 4323-4326. 10.1074/jbc.272.7.4323.CrossRefPubMed
11.
12.
Benhar M, Forrester MT, Stamler JS: Protein denitrosylation: enzymatic mechanisms and cellular functions. Nat Rev Mol Cell Biol. 2009, 10: 721-732.PubMed
13.
Marozkina NV, Wei C, Yemen S, Wallrabe H, Nagji AS, Liu L, Morozkina T, Jones DR, Gaston B: S-nitrosoglutathione reductase in human lung cancer. Am J Respir Cell Mol Biol. 2012, 46: 63-70. 10.1165/rcmb.2011-0147OC.CrossRefPubMedPubMedCentral
14.
Punathil T, Katiyar SK: Inhibition of non-small cell lung cancer cell migration by grape seed proanthocyanidins is mediated through the inhibition of nitric oxide, guanylate cyclase, and ERK1/2. Mol Carcinog. 2009, 48: 232-242. 10.1002/mc.20473.CrossRefPubMed
15.
Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW: Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010, 16: 1834-1844. 10.1158/1078-0432.CCR-09-3123.CrossRefPubMedPubMedCentral
16.
Foster MW, Hess DT, Stamler JS: Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med. 2009, 15: 391-404. 10.1016/j.molmed.2009.06.007.CrossRefPubMedPubMedCentral
Metadata
Title
S-nitrosylation of Ras in breast cancer
Authors
Harvey E Marshall
Matthew W Foster
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2012
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3331

Other articles of this Issue 6/2012

Breast Cancer Research 6/2012 Go to the issue

Research article

Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes

Editorial

Migratory gene expression signature predicts poor patient outcome: Are cancer stem cells to blame?

Viewpoint

Who do they think they are? Wnt-responsive cells reveal their family trees

Viewpoint

YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer

Research article

Modelling the overdiagnosis of breast cancer due to mammography screening in womenaged 40 to 49 in the United Kingdom

Viewpoint

MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits